Non-Inferiority Trials, Please, US FDA Implores Rheumatoid Arthritis Sponsors

RA drug development has been slow to revise the trial design paradigm despite agreement on the drawbacks of placebo controls and crossover elements, but FDA biostatistician Levin sees promise in non-inferiority designs.